**IMG\_8106**

SARS-CoV and SARS-like (SL) CoVs to evaluate the possibility of repurposed vaccines against COVID-19. This strategy will be helpful in the scenario of an outbreak, since much time can be saved, because preliminary evaluation, including in vitro studies, already would be completed for such vaccine candidates. Multiepitope subunit vaccines can be considered a promising preventive strategy against the ongoing COVID-19 pandemic. In silico and advanced immunoinformatic tools can be used to develop multiepitope subunit vaccines. The vaccines that are engineered by this technique can be further evaluated using docking studies and, if found effective, then can be further evaluated in animal models (365). Identifying epitopes that have the potential to become a vaccine candidate is critical to developing an effective vaccine against COVID-19. The immunoinformatics approach has been used for recognizing essential epitopes of cytotoxic T lymphocytes and B\_ cells from the surface glycoprotein of SARS-CoV-2. Recently, a few epitopes have been recognized from the SARS-CoV- 2 surface glycoprotein. The selected epitopes explored targeting molecular dynamic simulations,